Peer Review Plan for the Procedures for Developing the NIOSH List of Hazardous Drugs in Healthcare Settings
Title: Procedures for Developing the NIOSH List of Hazardous Drugs in Healthcare Settings
Anticipated Date of Dissemination: January 2018
Subject: Hazardous Drug Exposure in Healthcare Settings
Purpose: To describe the internal practices used by NIOSH to add or remove pharmaceutical substances to/from the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings.
Agency contact for information: firstname.lastname@example.org
Timing of Review: January 29, 2018 – February 28, 2018
Primary Disciplines or Expertise Needed for Review: pharmacy, nursing, pharmacology, occupational health, toxicology, veterinary medicine
Type of Review: Individual letters
Number of Reviewers: 4 — 10
Reviewers Selected by: CDC/NIOSH
Public Nominations Requested for Review Panel: No
Opportunities for the Public to Comment: Yes, Provide comments on this plan via email to the Agency contact identified above
Peer Reviewers Provided with Public Comments Before Their Review: No
Michael O. Childress DVM, MS, DACVIM
Associate Professor of Comparative Oncology
Dept Veterinary Clinical Sciences
Purdue College of Veterinary Medicine
Chun-Yip Hon PhD, CPHI(C), CIH, CRSP
School of Occupational and Public Health
Melissa McDiarmid, MD, MPH, DABT
Professor of Medicine and Epidemiology & Public Health
Director, Division of Occupational & Environmental Medicine
University of Maryland School of Medicine
AnnMarie Walton, PhD
Assistant Professor, School of Nursing
Charge to Peer Reviewers
- Does the draft policy and procedures clearly describe the process used by NIOSH to screen and evaluate drugs?
- Are the screening and evaluation categorization processes described by the draft policy and procedures scientifically sound?
- Is the set of information sources used for classifying drugs sufficient to identify relevant hazards? Are there other information sources that should be included?
- Is the threshold of information required to move from the screening process to the full evaluation process clearly described? Is the information threshold scientifically sound?
- Is the reconsideration process for addition or deletion of a drug to/from the hazardous drug list adequately described?
- Are there any issues not considered by the charge questions that should addressed?